5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction

This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effects of 5-alpha-reductase inhibitors (5ARIs) for treating lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO). © 2015 The Cochrane Collaboration.

Autores:
Tipo de recurso:
Fecha de publicación:
2015
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/23701
Acceso en línea:
https://doi.org/10.1002/14651858.CD011928
https://repository.urosario.edu.co/handle/10336/23701
Palabra clave:
Dutasteride
Finasteride
Steroid 5alpha reductase inhibitor
Article
Benign prostatic obstruction
Clinical protocol
Disease association
Disease severity
Drug effect
Human
International prostate symptom score
Lower urinary tract symptom
Outcome assessment
Priority journal
Prostate disease
Quality of life
Systematic review
Urine retention
Urogenital tract disease assessment
Rights
License
Abierto (Texto Completo)